RxSight, gained US FDA approved for a new type of Intraocular Lens for use after cataract surgery. It can be adjusted AFTER implantation in a patient. I was a founder of this firm which came out of University of California San Francisco (Dan Schwartz, M.D.) (originally named Calhoun Vision) many years ago.
The Dry Eye Workshop II (DEWS II) report, sponsored by the Tear Film and Ocular Surface Society, has now been published in the July 2017 issue of The Ocular Surface. There is an introduction, and 10 sub-committee reports, including the Clinical Trials and Regulatory Sub-Committee report of which Dr. Novack was the chair. This represents over 2 years work by 125+ worldwide researchers and clinicians. It supplants the 2007 report with the latest review of Dry Eye research. #TFOSDEWSII @aao_ophth
After more than 25 years of providing service, PharmaLogic has updated our logo. We’ve decided to incorporate an ocular theme. This is certainly because of our extensive work in developing novel therapies for ophthalmic disease. However, as evidenced by our track record, we also work in dermatology, neurology and other therapeutic areas. Further, this new logo conveys our ‘vision’ – a unique integrative approach to provide the optimal path forward for our clients in achieving their goals. We look forward to continuing to help our clients in developing novel therapies.